Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER ⁺ breast cancer.

Autor: Palafox M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Monserrat L; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Bellet M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Villacampa G; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Gonzalez-Perez A; Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.; Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain., Oliveira M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Ibrahimi N; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.; Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France., Kannan S; Bioinformatics Institute (A*STAR), Singapore, Singapore., Mina L; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain., Herrera-Abreu MT; The Breast Cancer Now Research Centre, London, UK., Òdena A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Capelán M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Azaro A; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Bruna A; Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Viaplana C; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Hernández J; Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain., Su F; Novartis Pharmaceuticals, East Hanover, NJ, USA., Lin K; Genentech, Inc., South San Francisco, California, USA., Clarke RB; Breast Biology Group, Manchester Breast Centre, Manchester, UK., Caldas C; Cancer Research UK, Cambridge, UK., Arribas J; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Michiels S; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.; Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France., García-Sanz A; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain., Turner NC; The Breast Cancer Now Research Centre, London, UK., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Department of Oncology, IOB Institute of Oncology, Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Verma CS; Bioinformatics Institute (A*STAR), Singapore, Singapore.; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, Singapore., Lopez-Bigas N; Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.; Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Scaltriti M; Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA., Arnedos M; Department of Medical Oncology, Gustave Roussy, Villejuif, France.; Inserm Unit U981, Villejuif, France., Saura C; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.

Publikováno v: Nature communications [Nat Commun] 2022 Nov 14; Vol. 13 (1), pp. 6928. Date of Electronic Publication: 2022 Nov 14.